Rosiglitazone plus metformin: Combination therapy for type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 6, 2004, Pages 1411-1422

  Del Prato, Stefano ^a   Volpe, Laura ^a  

^a CISANELLO HOSPITAL   (Italy)

Author keywords

Clinical efficacy; Rosiglitazone metformin combination therapy (Avandamet); Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENYLATE KINASE; ANTIRETROVIRUS AGENT; BIGUANIDE; C REACTIVE PROTEIN; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID; FIBRINOGEN; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ISOPHANE INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENFORMIN; PIOGLITAZONE; PLACEBO; PROINSULIN; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES CONTROL; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DYSLIPIDEMIA; EDEMA; FLUID RETENTION; FOOD DRUG INTERACTION; GASTRITIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GOVERNMENT REGULATION; HEADACHE; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIVER DISEASE; LIVER FUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; RISK ASSESSMENT; STRUCTURE ANALYSIS; TABLET FORMULATION;

CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 3042813607     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.6.1411     Document Type: Article

References (96)

1. ZIMMET P, ALBERTI KG, SHAW J: Global and societal implications of the diabetes epidemic. Nature (2001) 414:782-787.
2. SKYLER JS, ODDO C: Diabetes trends in the USA. Diabetes Metab. Res. Rev. (2002) 18(Suppl. 3):S21-S26.
3. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-853.
4. THE DCCT REPORT: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. (1993) 329:977-986.
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation (2002) 106:3143-3421.
6. GROOP LC, SALORANTA C, SHANK M, BONADONNA RC, FERRANNINI E, DEFRONZO RA: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. (1991) 72:96-107.
7. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352:854-865.
8. VAN GAAL LF, DE LEEUW IH: Rationale and options for combination therapy in the treatment of Type 2 diabetes. Diabetologia (2003) 46(Suppl. 1):M44-M50.
9. INZUCCHI SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA (2002) 287:360-372.
10. DEFRONZO RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. (1999) 131:281-303.
11. INZUCCHI SE, MAGGS DG, SPOLLETT GR et al.: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. (1998) 338:867-872.
12. WAGSTAFF AJ, GOA KL: Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs (2002) 62:1805-1837.
13. GIANNARELLI R, ARAGONA M, COPPELLI A, DEL PRATO S: Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. (2003) 29(4 Pt 2):6S28-6S35.
14. GlaxoSmithKline: Avandamet® (rosiglitazone maleate and metformin hydrochloride) prescribing information. GlaxoSmithKline, Research Triangle Park, NC 27709, USA (2003).
15. Bristol-Myers Squibb: Glucophage® (metformin hydrochloride tablets 500 and 850 mg) prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA (1997).
16. LEBOVITZ HE: Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab. Res. Rev. (2002) 18(Suppl. 2):S23-S29.
17. MIYAZAKI Y, GLASS L, TRIPLITT C et al.: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia (2001) 44:2210-2219.
18. MATTHAEI S, STUMVOLL M, KELLERER M, HARING HU: Pathophysiology and pharmacological treatment of insulin resistance. Endocr. Rev. (2000) 21:585-618.
19. STUMVOLL M: Thiazolidinediones - some recent developments. Expert Opin. Investig. Drugs. (2003) 12:1179-1187.
20. YOUNG PW, BUCKLE DR, CANTELLO BC et al.: Identification. of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J. Pharmacol. Exp. Ther. (1998) 284:751-759.
21. KAHN CR, CHEN L, COHEN SE: Unraveling the mechanism of action of thiazolidinediones. J. Clin. Invest. (2000) 106:1305-1307.
22. STUMVOLL M, HARING HU: Glitazones: clinical effects and molecular mechanisms. Ann. Med. (2002) 34:217-224.
23. MIYAZAKI Y, HE H, MANDARINO LJ, DEFRONZO RA: Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes (2003) 52:1943-1950.
24. HALLSTEN K, VIRTANEN KA, LONNQVIST F et al.: Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes (2002) 51:3479-3485.
25. CAREY DG, COWIN GJ, GALLOWAY GJ et al.: Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes. Res. (2002) 10:1008-1015.
26. MAYERSON AB, HUNDAL RS, DUFOUR S et al.: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes (2002) 51:797-802.
27. JUHL CB, HOLLINGDAL M, PORKSEN N, PRANGE A, LONNQVIST F, SCHMITZ O: Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J. Clin. Endocrinol. Metab. (2003) 88:3794-3800.
28. LEBOVITZ HE, DOLE JF, PATWARDHIAN R, RAPPORT EB, FREED MI: Rosiglitazone Clinical Trials Study Group. J. Clin. Endocrinol. Metab. (2001) 86:280-288.
29. CHARBONNEL B, LÖNNQVIST F, JONES NP, ABEL MG, PATWARDDHAN: Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 yar of treatment in type 2 diabetic patients. Diabetes (1999) 48(Suppl. 1):A114.
30. PORTER LE, FREED MI, JONES NP, BISWAS N: Rosiglitazone reduces proinsulin/insulin ratio and improves β-cell function in type 2 diabetes. Diabetologia (2000) 43(Suppl. 1):A192.
31. LUPI R, DEL GUERRA S, MARSELLI L et al.: Rosiglitazone prevents the impairment of human islet function induced by fatty-acids. Evidence for a role PPAR-{gamma}2 in the modulation of insulin secretion. Am. J. Physiol. Endocrinol. Metab. (2004) 286(4):E560-E567 (Epub 2003 Nov 18).
32. RICOTE M, HUANG J, FAJAS L et al.: Expression of the peroxime proliferators-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Natl. Acad. Sci. USA (1998) 95:7614-7619.
33. MARX N, BOURCIER T, SURKHOVA GK, LIBBY P, PLUTZKY J: PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. (1999) 19:546-551.
34. LAW RE, GOETZE S, XI XP et al.: Expression and function of PPARγ in rat and Human vascular smooth muscle cells. Circulation (2000) 101:1311-1318.
35. PATEL NG, HOLDER JC, SMITH SA, KUMAR S, EGGO MC: Differential regulation of lipogenesis and leptin production by independent signaling pathways and rosiglitazone during human adipocyte differentiation. Diabetes (2003) 52:43-50.
36. NEUSCHWANDER-TETRI BA, BRUNT EM, WEHMEIER KR, OLIVER D, BACON BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 38:1008-1017.
37. BAKRIS G, VIBERTI G, WESTON WM, HEISE M, PORTER LE, FREED MI: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J. Hum. Hypertens. (2003) 17:7-12.
38. PISTROSCH F, PASSAUER J, FISCHER S, FUECKER K, HANEFELD M, GROSS P: In Type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care (2004) 27:484-490.
39. CHOI SH, CHOI DH, KO YK et al.: Preventing effects of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Diabetes (2003) 52(Suppl.1):A19.
40. RYAN MJ, DIDION SP MATHUR S, FARACI FM, SIGMUND CD: PPAR{gamma} agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension (2004) 43(3):661-666.
41. SHARGORODSKY M, WAINSTEIN G, GAVISH E, LEIBOVITZ Z, MATAS D, ZIMLICHMAN R: Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am. J. Hypertens. (2003) 16:617-622.
42. RAJI A, SEELY EW, BEKINS SA, WILLIAMS GH, SIMONSON DC: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care (2003) 26:172-178.
43. HARTE AL, MCTERNAN PG, MCTERNAN CL, SMITH SA, BARNETT AH, KUMAR S: Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes. Metab. (2003) 5:302-310.
44. YKI-JARVINEN H, SUTINEN J, SILVEIRA A et al.: Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler. Thromb. Vasc. Biol. (2003) 23:688-694.
45. HAFFNER SM, GREENBERG AS, WESTON WM, CHEN H, WILLIAMS K, FREED MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation (2002) 106:679-684.
46. SIDHU JS, COWAN D, KASKI JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J. Am. Coll. Cardiol. (2003) 42:1757-1763.
47. MARX N, IMHOF A, FROEHLICH J et al.: Effect of rosiglitazone treatment on soluble CD40L in patients with Type 2 diabetes and coronary artery disease. Circulation (2003) 107:1954-1957.
48. YANG W-S, JENG CY, WU TJ et al.: Syntetic perxisome proliferator-activated. receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care (2002) 25:376-380.
49. FREED MI, RATNER R, MARCOVINA SM et al.: Effects of rosiglitazone alone and in combination with atorvastatin on metabolic abnormalities in type 2 diabetes mellitus. Am. J. Cardiol. (2002) 90:947-952.
50. KO SH, SONG KH, AHN YB et al.: The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus. Metabolism (2003) 52:731-734.
51. SUTINEN J, HAKKINEN AM, WESTERBACKA J et al.: Rosiglitazone in treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir. Ther. (2003)52:731-734.
52. VIBERTI GC: Rosiglitazone: potential beneficial impact on cardiovascular disease. Int. J. Clin. Pract. (2003) 57:128-134.
53. CUSI K, DEFRONZO RA: Metformin: a review of its metabolic effects. Diabetes Rev. (1998) 6:89-131.
54. HUNDAL RS, INZUCCHI SE: Metformin: new understandings, new uses. Drugs (2003) 63:1879-1894.
55. RADZIUK J, BAILEY CJ, WIERNSPERGER NF, YUDKIN JS: Metformin and its liver targets in the treatment of type 2 diabetes. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2003) 3:151-169.
56. FERY F, PLAT L, BALASSE EO: Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. Metabolism (1997) 46:227-233.
57. LEVERVE XM, GUIGAS B, DETAILLE D et al.: Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab. (2003) 29(4 Pt 2):6S88-6S94.
58. FLECHTNER-MORS M, DITSCHUNEIT HH, JENKINSON CP, ALT A, ADLER G: Metformin inhibits catecholamine-stimulated lipolysis in obese, hyperinsulinemic, hypertensive subjects in subcutaneous adipose tissue: an in situ microdialysis study. Diabetes Med. (1999) 16(12):1000-1006.
59. RICCIO A, DEL PRATO S, VIGILI DE KREUTZENBERG S, TIENGO A: Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin. Diabetes Metab. (1991) 17(1 Pt 2):180-184.
60. ZHOU G, MYERS R, LI Y et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. (2001) 108:1167-1174.
61. CORTON JM, GILLESPIE JG, HAWLEY SA, HARDIE DG: 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. (1995) 229:558-565.
62. WITTERS LA: The blooming of the French lilac. J. Clin. Invest. (2001) 108:1105-1057.
63. LUPI R, DEL GUERRA S, TELLINI C et al.: The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur. J. Pharmacol. (1999) 364:205-209.
64. LUPI R, DEL GUERRA S, FIERABRACCI V et al.: Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes (2002) 51(Suppl. 1):S134-S137.
65. ABBASI F, CHU JW, MCLAUGHLIN T, LAMENDOLA C, LEARY ET, REAVEN GM: Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism (2004) 53:159-164.
66. MAMPUTU JC, WIERNSPERGER NF, RENIER G: Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab. (2003) 29(4 Pt 2):6S71-6S76.
67. DESPRES JP: Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab. (2003) 29(4 Pt 2):6S53-6S61.
68. BEISSWENGER P, RUGGIERO-LOPEZ D: Metformin inhibition of glycation processes. Diabetes Metab. (2003) 29(4 Pt 2):6S95-6S103.
69. FRANCESCHINI G, PAOLETTI R: Drugs controlling triglyceride metabolism. Med. Res. Rev. (1993) 13:125-138.
70. GRANT P: Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. (2003) 29(4 Pt 2):6S44-6S52.
71. GIUGLIANO D, DE ROSA N, DI MARO G et al.: Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care (1993) 16:1387-1390.
72. DORELLA M, GIUSTO M, DA TOS V et al.: Improvement of insulin sensitività by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. Clin. Endocrinol. Metab. (1996) 81:1568-1574.
73. COX PJ, RYAN DA, HOLLIS FJ et al.: Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab. Dispos. (2000) 28:772-780.
74. TUCKER GT, CASEY C, PHILLIPS PJ, CONNOR H, WARD JD, WOODS HF: Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br. J. Clin. Pharmacol. (1981) 12:235-246.
75. SIRTORI CR, FRANCESCHINI G, GALLI-KIENLE M et al.: Disposition of metformin (N,N-dimethylbiguanide) in man. Clin. Pharmacol. Ther. (1978) 24:683-693.
76. BALDWIN SJ, CLARKE SE, CHENERY RJ: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br. J. Clin. Pharmacol. (1999) 48:424-432.
77. PATERL BR, DIRINGER K, CONRAD J et al.: Population pharmacokinetics of rosiglitazone in phase III clinical trials. Clin. Pharmacol. Ther. (2000) 67:123 (Abstract PII-33).
78. SAMBOL NC, CHIANG J, LIN ET et al.: Kidney function and age are both predictors of pharmacokinetics of metformin. J. Clin. Pharmacol. (1995) 35:1094-1102.
79. FONSECA V, ROSENSTOCK J, PATWARDHAN R, SALZMAN A: Effect of metformin and rosiglitazone combination therapy in patients with Type 2 diabetes mellitus: a randomized controlled trial. JAMA (2000) 283:1695-1702.
80. GOMEZ-PEREZ FJ, FANGHÄNEL-SALMON G, BARBOSA JA et al.: Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab. Res. Rev. (2002) 18:127-134.
81. JONES TA, SUTTER M, VAN GAAL LF, JONES NP: Adddition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes. Metab. (2003) 5:163-170.
82. BALLARY C, DESAI A: Drug trial report: efficacy and safety of combination of metformin and rosiglitazone in patients with Type 2 diabetes mellitus. A postmarketing study. JAMA (2003) 101:1-5.
83. POULSEN MK, HENRIKSEN JE, HOTHER-NIELSEN O, BECK-NIELSEN H: The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care (2003) 26:3273-3279.
84. ROSNSTOCK J, GOLDSTEIN B, WOODDEL M, STROW LJ, WATERHOUSE R, COBITZ AR: Study 284 (EMPIRE) Greater benefits of rosiglitazone (RSG) added to submaximal dose of metformin (MET) compared to maximizing metformin dose in type 2 diabetes mellitus (T2DM) patients. Diabetes (2004) 53:A.
85. WOLFFENBUTTEL BH, GOMIS R, SQUATRITO S, JONES NP, PATWARDHAN RN: Addition of low-dose rosiglitazone to sulphanylurea therapy improve glycemic control in Type 2 diabetic patients. Diabet Med. (2000) 17(1):40-47.
86. ROSENSTOCK J, PORTER MA, HEISE, O'NEILL MC, KRAVITZ B, FREED MI, THE ROSIGLITAZONE 135 STUDY GROUP: Type 2 diabetes in the elderly: reaching durable glycemic goals with combination sulfonalnylurea and rosiglitazone. Diabetes Metab. (2003) 29:S247-S248.
87. HAMMAN A, MATTHAEL S, MAUERSBERGER H et al.: Efficacy and safety of rosiglitazone in combination with glimperide. Diabetes Metab. (2003) 29:4S249.
88. NESTO RW, BELL D, BONOW RO et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from American Heart Association and American Diabetes Association. Diabetes Care (2004) 27:256-263.
89. GlaxoSmithKline: Avandia® (rosiglitazone maleate) package insert. GlaxoSmithKline, Philadelphia, PA, USA 2000.
90. MAGGIO CA, PI-SUNYER FX: Obesity and type 2 diabetes. Endocrinol. Metab. Clin. North Am. (2003) 32(4):805-822.
91. BRAY GA: Risks of obesity. Endocrinol. Metab. Clin. North Am. (2003) 32:787-804.
92. MELIKIAN C, WHITE TJ, VANDERPLAS A, DEZII CM, CHANG E: Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin. Ther. (2002) 24:460-467.
93. TURNER RC, CULL CA, FRIGHI V, HOLMAN RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA (1999) 281:2005-2012.
94. DEL GUERRA S, LUPI R, MARSELLI L et al.: Metformin ameliorates function and survival of pancreatic islets isolated from Type 2 diabetic patients. Diabetologia (2003) 46(Suppl 2):A169.
95. FINEGOOD DT, MCARTHUR MD, KOJWANG D et al.: Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes (2001) 50:1021-1029.
96. BELL DS: Beta-cell rejuvenation with thiazolidinediones. Am. J. Med. (2003) 115(Suppl 8A):20S-23S.